

TODD ERIC SCHLESINGER, MD, FAAD
Curriculum Vitae

Dermatology & Laser Center of Charleston
2180 Henry Tecklenburg Drive
Charleston, SC 29414

Clinical Research Center of the Carolinas
1364 Ashley River Road
Charleston, SC 29407

Phone: (843) 556-8886

Fax: (843) 556-8850

EMPLOYMENT

Dermatology & Laser Center of Charleston – Charleston, South Carolina

Clinical Research Center of the Carolinas - Charleston, South Carolina

· Medical Director, Founder

· July 2005 – present, group private dermatology practice and clinical research center

Consultant

- Projects include services to pharmaceutical companies, over the counter manufacturers, and biotechnology firms nationally and internationally
- Details available upon request

Dermatology Associates of the Low Country – Hilton Head, South Carolina

· Physician

· July 1998 – June 2005

BOARD CERTIFICATION

Board Certified in Dermatology, 1998, Recertified 2006 for 2008-2019, Recertified 2019-2029

STATE LICENSURE

State Licensed in Florida, Pennsylvania, and South Carolina

HOSPITAL AFFILIATION

Bon Secours St. Francis Medical Center – Active Staff 2005-present

Roper Hospital – Courtesy Staff 2005-present

Ralph H. Johnson VA Medical Center – Active Staff 2007-2011

ACADEMIC AFFILIATION

Clinical Instructor, Department of Dermatology

- State University of New York at Buffalo, School of Medicine and Biomedical Sciences - November 2015-present

Affiliate Assistant Professor, College of Medicine

- Medical University of South Carolina, October 2013-present

Clinical Preceptor, College of Health Professions

- Medical University of South Carolina, July 2010-present

Clinical Assistant Professor, Department of Dermatology

- Medical University of South Carolina, July 2007 – July 2011

SOCIETY MEMBERSHIPS AND APPOINTMENTS

Fellow, American Society for Mohs Surgery

Fellow, American Academy of Dermatology

- Performance Measurement Work Group 2007-2012
- State Society Development Task Force 2009-2015
- Editorial Board, Dialogues in Dermatology 2015-2018, reappointed for 2019-2021 Deputy Editor, and then automatically to Editor for 2021-2023
- AAD Actinic Keratosis Guideline Committee, Co-Chair, Appointed late 2018 for 2019-2021 (until complete)

Fellow, American Society for Dermatologic Surgery

- Website Work Group 2008-2010

Fellow, American Society for Laser Medicine and Surgery

- Constitution and Bylaws Committee Member 2005-2006

Member, South Carolina Medical Association

- President, Executive Committee 2019-2020
- President-Elect, Executive Committee, 2018-2019
- Chairman of the Board, Executive Committee, 2016-2018
- Vice Chairman of the Board, Executive Committee, 2014-2016

- Member-at-Large, Executive Committee, 2013-2014
- Board of Trustees 2007-2009, 2010-present
- Treasurer (Executive Committee Member), 2010-2011
- Board of Trustees 2011-present

Board directs operation of an \$8M state medical association representing 40% of the physicians in South Carolina.

Member, American Society of Phlebology

Member, American Medical Association

Alternate Delegate from South Carolina Medical Association 2017-Present

Member, Board of Directors, Executive Committee, Charleston County Medical Society

- President – 2016-2017
- Chair – Young Physician’s Task Force – 2008-2013
- Chair - Hospital Relations Committee - 2013-2015

Member, Global Directory of Who’s Who

Past Delegate, 1st Medical District to South Carolina Medical Association 1999-2007

South Carolina Dermatological Association

- President 2007-2008

Past Chair, Young Physician’s Section, South Carolina Medical Association 2006-2007

Editorial Board Member - New DermMD, a publication of Bryn Mawr Communications III, LLC

Editorial Advisory Board, Journal of Clinical and Aesthetic Dermatology, 2016-present

Editorial Board, SkinMed Journal, 2017-present

Host, Practically Speaking (A Bryn Mawr Communications III, LLC Podcast), 2016-present

Board of Advisors, Remedy.com (An integrated software platform for medical practices), 2017-present

Member, Joint Underwriting Association Board of Directors 2010-2016

Board directs operation of a 50M medical malpractice insurance carrier representing a large portion of physicians in South Carolina.

EDUCATION

Residency in Dermatology - *Cleveland Clinic Foundation, Cleveland, OH*

- July 1995 - June 1998

Internship in Internal Medicine - *Cleveland Clinic Foundation, Cleveland, OH*

- July 1994 - June 1995

M.D. *School of Medicine and Biomedical Sciences*

State University of New York at Buffalo (SUNY). Buffalo, New York

- August 1990 - June 1994
- Alpha Omega Alpha Buffalo Epsilon Chapter, junior year
- Gibson Anatomical Honor Society, inducted 1991
- Pathology Honor Society, inducted 1994

B.A. *State University of New York at Buffalo, Buffalo, New York*

- September 1986 - June 1990
- Major: Economics
- Minor: Biology
- Phi Beta Kappa, elected 1990

23rd Combined Skin Pathology Course – Pittsburgh, Pennsylvania

- July 24-29, 2009

Superficial Anatomy and Cutaneous Surgery – *Scripps Clinic, La Jolla, California*

- June 14-19, 2004

American Society for Mohs Surgery – Completion of requirements to become a Fellow Member

- October, 2003

AWARDS

- Castle Connolly Top Doctor – Charleston, SC – Awarded in 2017, 2018
- Cleveland Clinic 2007 Innovator Award – Neutraceutical Line for Skin Rejuvenation
- President's 2009 Volunteer Service Award – Corporation for National and Community Service
- Westie Award for Volunteer Hours and Charitable Giving 2010 – West of Community Newspaper
- South Carolina Dermatologist of the Year 2019-2020 – South Carolina Academy of Dermatology and Dermatologic Surgery

PHARMACEUTICAL RESEARCH

- Atrix Acne Study - double blind controlled trial investigating topical dapsone (now marketed as Aczone)
- Novartis Lamisil pulse dose study for onychomycosis
- Amgen – EASE Study for Enbrel
- Glaxo Smith Kline - Avandia Psoriasis Study

- Genentech RESPONSE Trial Altana Study - HPA Axis evaluation with topical steroid Pandel
- Ferndale – PICTURE THE DIFFERENCE postmarketing observational study with topical steroid Locoid
- Amgen – OBSERVE-5 multicenter phase IV study with Enbrel for
- Galderma – COBRA TRIAL multicenter phase IV study with Clobex spray for psoriasis
- Centocor Ortho Biotech Services (now Janssen Biotech) – Psoriasis Longitudinal Assessment and Registry (PSOLAR)
- Galderma – ADHERENCE multicenter observational acne study
- Centocor - RESPONSE 8 year multicenter registry for psoriasis and psoriatic arthritis patients who are candidates for systemic
- JSJ Pharmaceuticals – chemical peel study – a prospective clinical outcome trial of a novel chemical peel
- JSJ Pharmaceuticals – Vitivia Topical Vitamin Study
- Abbott Pharmaceuticals – ESPRIT The Abbott Psoriasis Registry
- River’s Edge Pharmaceuticals - A randomized, double blind comparative trial of two formulations of 5.25% topical benzoyl peroxide gel for acne
- JSJ Pharmaceuticals – Act Now with Inova Acne Control Therapy – An 8-week efficacy study with Inova
- Galderma Laboratories – Oracea for Rosacea: A Community Based Assessment (ORCA) Trial – Clinical study evaluating the safety and effectiveness of Oracea (doxycycline USP) Capsules 40mg
- Tiber Laboratories – Efficacy of Zenieva cream for dermatitis. An open-label efficacy trial
- Astellas Pharma Global Development – APPLES: A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis
- Photocure ASA - Split Face Study of Facial Rejuvenation for Fine Line Wrinkles using Blue Light and microdermabrasion after Topical Application of an ester of Aminolevulinic Acid (Allumera)
- Photocure ASA - Study of Improvement in the Appearance of Darkly Pigmented Skin Type using Blue Light and Microdermabrasion after Topical Application of an ester of Aminolevulinic Acid (Allumera)
- Pierre Fabre Laboratories – Pilot Study of a New Acne Line – Photographic Analysis and Quality of Life Measurement
- Quasar BioTech, LLC – Investigator – New Device, trial closed by sponsor
- Innocutis - Study of the Efficacy and Tolerability of Bionect Cream in Rosacea
- Innocutis - Study of the Efficacy and Tolerability of Bionect Gel in Seborrheic Dermatitis
- Genentech - RegiSONIC: A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients

- Genentech – MIKIE: A Randomized, Double-Blinded, Regimen-Controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients with Multiple Basal Cell Carcinomas
- Amgen – An Open-Label, Randomized, Cross-over Study to Assess the Preference for Autoinjector A versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated with Etanercept
- Allergan – A Safety and Efficacy Study to Compare Dapsone Dermal Gel with Vehicle Control in Patients with Acne Vulgaris
- Coherus Biosciences - A Double-Blind, Randomized, Parallel Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects with Chronic Plaque Psoriasis
- Galderma – A multicenter, randomized, double blind, parallel group, vehicle-controlled study of the safety and efficacy of calcitriol 3mcg/g ointment applied twice daily for 8 weeks in pediatric subjects (2 to 12 years of age) with mild to moderate plaque psoriasis
- Sebacia - A Randomized, Prospective, Multicenter, Controlled Study with Blinded Assessment to Determine the Safety and Effectiveness of the Sebacia Acne Treatment System in the Treatment of Inflammatory Acne Vulgaris
- MedImmune - A Phase 2b, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Tralokinumab in Adult Subjects with Moderate-to-Severe Atopic Dermatitis
- Anterios – Clinical Trial to Evaluate ANT-1207 in the Treatment of Primary Axillary Hyperhidrosis in Adults
- Celgene – A Phase 4, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004), in Subjects with Moderate Plaque Psoriasis
- Dermira – A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Efficacy and Safety Study of DRM04 in Subjects with Axillary Hyperhidrosis
- Dermira – A Open Label- Study Assessing Long-Term Safety of DRM04 in Subjects with Primary Axillary Hyperhidrosis
- Valeant – A Phase 3, Multi-Center, Open Label Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis
- Valeant – A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
- Corrona – Corrona Psoriasis Registry (Corrona-PSO-500)
- Suneva – A Pilot Study to Evaluate the Safety and Effectiveness of Microneedling and Bellafill to Treat Facial Acne Scars
- Cutanea Life Sciences – A Phase 3, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle Administered for 12 Weeks to Subjects with Papulopustular Rosacea with a 4 Week Follow-up Period

- Sienna Labs – Clinical investigation of a Topical Nanoparticle Followed by 755 nm Laser for the Treatment of Acne Vulgaris in Facial Areas of Healthy Subjects
- Galderma – Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study to Compare the Efficacy and Safety of CD5789 50 µg/g Cream Versus Vehicle Cream in Subjects with Acne Vulgaris
- Galderma – Efficacy and Safety of Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel Plus Doxycycline in Severe Inflammatory Acne (Non-Nodulocystic) Subjects
- Leo – A Phase 2 Trial Evaluating the Safety and Efficacy of Once Daily Use of LEO 80185 Gel Containing Calcipotriol 50 µg/g Plus Betamethasone 0.5mg/g (As Dipropionate) in Adolescent Subjects (aged 12 to 16 years, 11 months) With Scalp and Body Psoriasis
- Novan – A Phase 3 Multi-Center, Randomized, Double-Blinded, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy, Tolerability, and Safety of SB204 and Vehicle Gel Once Daily in the Treatment of Acne Vulgaris
- Actelion - A PROspective, observational, US-based study assessing outcomes, adverse events, treatment patterns, and quality of life in patients diagnosed with mycosis fungoides cutaneous T-cell lymphoma and treated with Valchlor
- Leo Pharma Inc. - Effect of Calcipotriol plus Betamethasone Dipropionate Gel on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 16 Years, 11 months) with Scalp and Body Psoriasis
- Athenex (formerly Kinex) – A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment 1% in Subjects with Actinic Keratosis on the Face or Scalp
- Allergan – A Multicenter, Single-blind, Randomized, Controlled Study of the Safety and Effectiveness of JUVEDERM VOLUMA XC Injectable Gel for Chin Augmentation
- Boehringer Ingelheim - Phase III, multicenter, randomized, double blind trial of the safety and efficacy of BI 655066 in patients with moderate to severe plaque psoriasis: Induction and maintenance vs. active comparator (ustekinumab)
- Novartis – A 52-week, Multicenter, Randomized, Double-blind Study of Secukinumab (300mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator’s Global Assessment after 12 weeks of Treatment, compared to Ustekinumab, and to assess long term safety, tolerability, and efficacy in subjects with moderate to severe plaque psoriasis
- Regeneron – A Phase 2 Study of REGN2810, A Fully Human Monoclonal Antibody to Programmed Death – 1 (PD-1), in Patients with Advanced Cutaneous Squamous Cell Carcinoma
- Leo Pharma Inc – A Randomized, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects with Moderate-to-Severe Atopic Dermatitis who are Candidates for Systemic Therapy
- Sienna Labs – A Multicenter, Double-blind, Nontreatment, Long-term, Follow-up Study of Subjects Who Completed Clinical Studies 755.1100_FA, 810.1100_FA, or

1064.1100_FA of a Topical Silver Particle Solution Followed by Laser for the Treatment of Facial Acne Vulgaris

- AbbVie – A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS)
- Bayer – Investigator Initiated – Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea: An Evaluation of Photographic Evidence
- Regeneron – A Phase 2 Study of Regn2810, A Fully Human Monoclonal Antibody to Programmed Death-1, in Patients with Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
- Cutanea -A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CLS006 versus Vehicle in Subjects 2 years of age or older with Cutaneous Common Warts
- Akros - A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of JTE-051 Administered for 12 Weeks in Subjects with Moderate to Severe Plaque Psoriasis (CLEAR-PS)
- Athenex - A Phase 3, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy and Safety Study of KX2-391 Ointment 1% in Adult Subjects with Actinic Keratosis on the Face or Scalp
- Leo Pharma Inc /Skin Sciences, PLLC - Investigator Initiated- Efficacy and Safety of Enstilar Foam in Combination with Aprimelast in Patients with Moderate Plaque Psoriasis
- Eli Lilly – I4V-MC-JAIW A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis
- Eli Lilly – Protocol I4V-MC-JAIX A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis
- Eli Lilly – 16T-MC-AMAJ A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients with Moderate to Severe Plaque Psoriasis (OASIS-2)
- Eli Lilly – Protocol I6T-MC-AMAH A Multicenter, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment Effect of Mirikizumab in Patients with Moderate-to-Severe Plaque Psoriasis OASIS-3
- Merz – Evaluation of Effectiveness and Safety of Radiesse (+) for the Improvement of Jawline Volume and Contour
- Dermira – Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients with Moderate to Severe Atopic Dermatitis

- Leo – Phase 3 Open-Label, Single-Arm, Long-Term Extension Trial to Evaluate the Safety and Efficacy of Tralokinumab in Subjects with Atopic Dermatitis who Participated in Previous Tralokinumab Clinical Trials
- Sisaf – Investigator Initiated - Open-Label Study, Evaluate the Efficacy and Tolerability of Salicylic Acid 1% and ProSilic® (SIS008) Cream Alone Compared to Salicylic Acid 1 % and ProSilic® (SIS008) Cream Plus Benzoyl Peroxide 5% and ProSilic® (SIS008-BP1) Cream for the Treatment of Mild to Moderate Acne
- Kiniksa – A Phase 1b, Double-Blind, Randomized, Placebo Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Repeated Doses of KPL-716
- AbbVie – A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
- Aclaris – A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice a Week in Subjects with Common Warts
- Novartis – A Randomized, Double-Blind, Multicenter Study Assessing Short (16 weeks) and Long-Term Efficacy (up to 1 year), Safety, and Tolerability of Sub-Cutaneous Secukinumab in Subjects of Body Weight 90 kg or Higher with Moderate to Severe Chronic Plaque-Type Psoriasis
- Novartis – A 16-Week Randomized, Open-Label, Multicenter Study to Assess the Superiority of Secukinumab Over Guselkumab in the Complete Treatment of Ustekinumab-Resistant Psoriatic Plaques – Arrow
- Bristol-Myers Squibb – Randomized, Double-Blind, Placebo and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Plaque Psoriasis
- Nestle Skin Health and Advanced Clinical – A Randomized, Evaluator-Blinded, Parallel, Comparator-Controlled Study to Evaluate the Safety and Effectiveness of GAL1704 for Cheek Augmentation and Correction of Midface Contour Deficiencies
- Lilly – A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis
- Allergan – A Randomized, Multicenter, Evaluator-Blind, Controlled Study to Evaluate the Safety and Effectiveness of Juvederm Volite XC Injectable Gel for the Correction of Fine Lines on the Cheek
- Boehringer Ingelheim – Phase II Evaluation of Safety, Tolerability, and Efficacy of BI 730357 in Patients with Moderate to Severe Plaque Psoriasis
- Boehringer Ingelheim – Phase II long- term extension study to assess the safety, tolerability and efficacy of BI 730357 in patients with moderate to severe plaque psoriasis
- Celgene - A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Mild to Moderate Plaque Psoriasis

- Novartis - A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa (SUNSHINE)
- Novartis - A Multicenter, Double-blind, Randomized Withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenitis suppurativa
- ChemoCentryx – A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa
- Biofrontera – A randomized, double blind, vehicle-controlled multicenter phase III study to evaluate the safety and efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the treatment of superficial basal cell carcinoma (sBCC) with photodynamic therapy (PDT)
- Pfizer – Investigator Initiated - Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis using a Combination Treatment of Crisaborole Ointment 2% and a Concomitant Topical Corticosteroid over a 8 week period
- Pfizer - A Phase 3 Randomized, Double Blind, Double Dummy, Placebo-Controlled, Parallel Group, Multi-Center Study Investigating the Efficacy and Safety of PF-04965842 and Dupilumab in Comparison with Placebo in Adult Subjects on Background Topical Therapy, With Moderate to Severe Atopic Dermatitis
- Dermavant – A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Plaque Psoriasis in Adults
- Dermavant – A Long-Term, Open-Label, Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream, 1% for the Treatment of Plaque Psoriasis in Adults
- DT Collagen - A Single Center, Open-Label Pilot Study to Evaluate the Safety and Efficacy of DT Skin Lightener in Subjects with Melasma
- TetraDerm Group, LLC – A Single Center, Open-Label Pilot Study to Evaluate the Safety and Efficacy of TETROS cream for the Support of Wound Healing Post-operatively to Microneedling and Carbon Dioxide Laser Ablative Resurfacing on Non-facial Skin
- Sanofi – A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients with Moderate to Severe Atopic Dermatitis
- Galderma – A Randomized, Double-Blind, Placebo-Controlled Study to Assess Immunization Responses in Adult and Adolescent Subjects with Moderate-to-Severe Atopic Dermatitis Treated with Nemolizumab
- Novartis Pharmaceuticals - A randomized, subject and investigator blinded, placebo-controlled, multi-center study in parallel groups to assess the efficacy and safety of LYS006 in patients with moderate to severe inflammatory acne
- Castle Biosciences Inc – Development and Validation of a Gene Expression Assay to Predict the Risk of Recurrence Disease in Cutaneous Squamous Cell Carcinoma

- Galderma Research & Development A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream in the Treatment of Thin and Moderately Thick, Non-hyperkeratotic, Non pigmented Actinic Keratosis of the Face and Scalp When Using Daylight Photodynamic Therapy (DL-PDT)
- Dermira – Randomized, Double-Blind, Placebo-Controlled trial to Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination with Topical Corticosteroid Treatment in Patients with Moderate to Severe Atopic Dermatitis
- Dermira - A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients with Moderate to Severe Atopic Dermatitis
- AOBiome Therapeutics - Randomized, Double-Blind, Vehicle Controlled Study of the Efficacy, Safety, and Tolerability of B244 Topical Spray for the Treatment of Pruritus in Adults with a History of Atopic Dermatitis
- Arcutis Biotherapeutics - A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects with Chronic Plaque Psoriasis
- Arcutis Biotherapeutics - A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Subjects with Chronic Plaque Psoriasis who have Completed Preceding Studies ARQ-151-301 or ARQ-151-302
- Sanofi - A randomized, double blind, placebo-controlled, multicenter, parallel group study to evaluate the efficacy and safety of dupilumab in patients with prurigo nodularis who are inadequately controlled on topical prescription therapies or when those therapies are not advisable.
- Novartis - A proof of concept study to evaluate the efficacy, safety and tolerability of secukinumab 300 mg over 32 weeks in adult patients with biopsy-proven forms of lichen planus not adequately controlled with topical therapies – PRELUDE
- Brickell Biotech - A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied Sofpironium Bromide Gel, 15% in Subjects with Axillary Hyperhidrosis
- Galderma Research & Development - A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Compare Efficacy and Safety of Trifarotene (CD5789) Cream When Used with an Oral Antibiotic for the Treatment of Severe Acne Vulgaris
- Trevi Therapeutics - A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm Study of the Anti-Pruritic Efficacy and Safety of Nalbuphine ER Tablets in Prurigo Nodularis
- Concert Pharmaceutical - Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata
- Prolacta Bioscience – Investigator Initiated - A Single Center, Open-Label Pilot Study to Evaluate the Tolerability and Safety of PBCLN-006 in Temporarily Relieving the Local Signs and Symptoms Associated with Mild to Moderate Plaque Psoriasis.

DERMATOLOGICAL RESEARCH

- 1997-2002 Retrospective Chart-Review Study of Drug-Induced Toxic Epidermal Necrolysis.
- 2015 Comparison of the Pharmacoeconomic Profiles of Treatment Regimens for Field Pattern Actinic Keratosis – Under grant from DUSA Pharmaceuticals.

OTHER RESEARCH EXPERIENCE**Graduate Research:**

Schlesinger TE, Shanler S, Mang T, Wilson BD. *Histopathologic mechanisms of photodynamic therapy of human nonmelanoma cutaneous carcinoma*. PDT Center, Roswell Park Memorial Institute, Buffalo, New York 14263. Poster at the SUNY School of Medicine Student Research Forum, December 7, 1992

Undergraduate Research:

- 1988-1989 University at Buffalo, Department of Molecular Biology
- 1990 Veterans Administration Hospital, Buffalo, New York, Department of Immunology

NATIONAL CANCER INSTITUTE (NCI) CLINICAL FELLOWSHIP

Clinical Dermatologic Oncology (Summer, 1991) Roswell Park Memorial Institute, Buffalo, New York. Preceptor: Dr. Howard Stoll Jr., M.D. Project report submitted upon completion.

OTHER ACTIVITIES

- 2011-2014 Consultant, InnoCUTIS Pharmaceuticals, LLC (Purchased by CIPHER)
- 2011-2012 , 2015-present Medical Advisory Board, National Trainer, Suneva Medical
- 2015-present Bayer Healthcare, Speaker's Bureau
- 2015-present DUSA Pharmaceuticals, Speaker's Bureau
- 2011-present Professional Expert Evaluation Review (PEER) Program Participant

2009-2010	National Educator, L'Oreal Corporation, SkinCeuticals Division
2007	Leadership Forum, American Academy of Dermatology
2010	Peer to Peer Educator, Medicis Corporation
1996-1998	Volunteer Dermatologist, Cleveland Free Clinic
1995	Cutaneous Resurfacing Workshop at the Ohio Society for Dermatologic Surgery meeting, Columbus, Ohio

VOLUNTEERISM AND COMMUNITY SERVICE

2006-2017	Organizer, Roper St. Francis Free Skin Cancer Screening Program
2008 and 2010	Participant, South Carolina Annual Statehouse Skin Cancer Screening
2017-Present	Organizer, Dermatology & Laser Center of Charleston Free Skin Cancer Screening Program <i>Free Skin Cancer Screening Program offered during Melanoma Awareness Month and at other times during the year</i>
2008-2011	Board of Directors, Jewish Community Center of Charleston
2011-2013	Board of Directors, Addlestone Hebrew Academy
2007-Present	Preceptor, Medical University of South Carolina, College of Health Professions, Physician Assistant Program
2009	President's Volunteer Service Award
2014-Present	Volunteer – Race the Landing, Charleston, South Carolina

PUBLICATIONS

Todd Schlesinger, Neal Bhatia, Brian Berman, Ayman Grada, Albert Torra, David Cutler and Mark Lebwohl. *Favorable Safety Profile of Tirbanibulin Ointment 1% for Actinic Keratosis: Pooled Results from Two Phase III Studies*. Presented as a poster at the 40th Annual Fall Clinical Dermatology Conference. Virtual Presentation, October 29-November 1, 2020.

Andrew Blauvelt, Steven Kempers, **Todd Schlesinger**, Edward Lain, Hui Wang, David Cutler, Mark Lebwohl, Jane Fang and Rudolph Kwan. *Tirbanibulin Ointment 1% for Actinic keratosis (AK): Pooled Data from Two Phase 3 Studies*. Presented as a poster at the 40th Annual Fall Clinical Dermatology Conference. Virtual Presentation, October 29-November 1, 2020.

Todd Schlesinger and Clinton Favre. *Improvement in Short-Term Outcome of Atopic Dermatitis Using a Combination Treatment of Crisaborole Ointment 2% and a Concomitant Topical Corticosteroid Over an 8-Week Period: An Interim Evaluation with Photographic Evidence*. Presented as a Poster at the 2020 Annual Meeting of the American Academy of Dermatology Virtual Meeting (VMX), March 20-24, 2020.

Armstrong A, **Schlesinger T**, Gopalan R, Drew J, Weisman, J and Guttman-Yassky E. *Lebrikizumab, a High Affinity IL-13 Inhibitor, Improves Moderate-to-Severe Atopic Dermatitis Across Racial Groups: Post-hoc Efficacy and Safety Analysis From a Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study*. 16th

- Annual Skin of Color Society's Scientific Symposium. Virtual Presentation March 19, 2020.
- Schmults CD, Ferris RL, Freeman M, Guild V, Koyfman S, Migden MR, Pavlick A, Rabinowits G, **Schlesinger T**, Swanson N, Wolf GT, Dinehart SM. *A Multidisciplinary Expert-Driven Consensus on the Evolving Treatment of Patients with Advanced Cutaneous Squamous Cell Carcinoma*. Presented as a Poster at Maui Derm for Dermatologists 2020 January 25-29, 2020, Maui, Hawaii.
- Migden MR, **Schlesinger TE**, Schmults CD, et al. *A Multidisciplinary Expert-driven Consensus on the Evolving Treatment of Patients with Advanced Cutaneous Squamous Cell Carcinoma*. Presented as a poster at the 39th Annual Fall Clinical Dermatology Conference, Las Vegas, NV October 17-20, 2019.
- Dinehart SM, Migden MR, **Schlesinger TE** et al. *A Multidisciplinary Expert-driven Consensus on the Evolving Treatment of Patients with Advanced Cutaneous Squamous Cell Carcinoma*. Presented as a poster at the 28th European Academy of Dermatology and Venereology (EADV), Madrid, Spain, October 9-13, 2019.
- St. Surin-Lord, **Schlesinger TE**, Guenin E. *Novel Tretinoin 0.05% Lotion for the Once-daily Treatment of Moderate-to-severe Acne Vulgaris in a Preadolescent and Adolescent Population*. *J Clin Aesthetic Dermatol*. 2019;12(9):E57-E61.
- Schlesinger TE**, Roberts W, Lehman A. *Post-Marketing Safety Experience of PMMA-Collagen Gel Dermal Filler*. Presented as a poster at the 2019 Women's Dermatologic Society 46th Annual Meeting & Luncheon, Washington, DC, February 28-March 3, 2019.
- Schlesinger TE**, Favre C. *Enhancing Outcomes in Seborrheic Keratosis: Using a Novel Treatment Solution*. *J Drugs Dermatol*. 2019;18(7 Suppl):s178-182.
- Schlesinger TE**, Favre C. *Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea: An Evaluation of Photographic Evidence*. Presented as an electronic poster at the 24th World Congress of Dermatology – WCD 2019, Milan, June 10-15, 2019.
- Schlesinger TE**. *Acne and Obesity: A Nationwide Study of 600,404 Adolescents*. PracticeUpdate website. Available at <https://www.practiceupdate.com/content/acne-and-obesity-in-adolescents/82331/65/4/1>. Accessed April 26, 2019.
- Biesman B, Cohen J, Dibernardo B, Emer J, Geronemus R, Gold M, Lehman A, Pilcher B, Monheit G, **Schlesinger T**, Teller C. *Treatment of Atrophic Facial Acne Scars With Microneedling Followed by Polymethylmethacrylate-Collagen Gel Dermal Filler*. *Dermatol Surg*. 2019;00:1-10.
- Keaney T, **Schlesinger T**, Chiu A, et al. *Best Practice for the Use of ATX-101 for Submental Contouring*. Presented as a poster at the 2018 American Society for Dermatologic Surgery Annual Meeting. October 11-14, 2018

- Schlesinger T**, Lehman A. *Post-Marketing Safety Experience of PMMA-Collagen Gel Dermal Filler*. Presented as a poster at the 2018 American Society for Dermatologic Surgery Annual Meeting. October 11-14, 2018
- Keaney T, **Schlesinger T**, Chiu A, et al. *Best Practice for the Use of ATX-101 for Submental Contouring*. Presented as a poster at the 2018 Cosmetic Boot Camp. June 21-24, 2018
- Bhatia A, Hsu J, **Schlesinger T**, Weiss R. *Optimizing Wound Healing for Cosmetic and Medical Dermatologic Procedures*. *Practical Dermatology*. March 2018;42-45
- Biesman B, Cohen J, DiBernardo B, Emer J, Geronemus R, Gold M, **Schlesinger T**, Teller C. *Treatment of Facial Acne Scars with Microneedling Followed by Polymethylmethacrylate (PMMA) Collagen Dermal Filler*. Presented as a poster at the 2018 American Society of Laser Medicine and Surgery Annual Meeting April 11-15, 2018.
- Schlesinger T**, Bruce S, Callender V, Cohen S et al. *Correction of distensible atrophic acne scars of the face using Bellafill, a PMMA-Collagen Dermal Filler*. Presented as a poster at the 2017 American Society for Dermatologic Surgery Annual Meeting October 5-8, 2017.
- Schlesinger T**. Not Every Patient Needs Triglyceride Check, but All Can Get Pancreatitis: A Systematic Review and Clinical Characterization of Isotretinoin Associated Pancreatitis. PracticeUpdate website. Available at: <http://www.practiceupdate.com/content/systematic-review-reveals-patients-on-isotretinoin-at-risk-for-pancreatitis-regardless-of-triglyceride-levels/47230/65/4/1>. Accessed January 11, 2017
- Schlesinger, TE**, Mills, OH, Criscito MC, Verdicchio R, Szoke, JD. *Addressing Free Radical Oxidation in Acne Vulgaris*. *J Clin Aesthet Dermatol*. 2016;9(1):25-30.
- Schlesinger, TE**, "Device Clinical Trials." *Clinical Dermatology Trials 101/A Primer for Dermatologists*. Ed. Adnan Nasir. New York: Springer, 2015. 59-72. Print.
- Schlesinger TE**, Powell CR. *Efficacy and Safety of a Low Molecular Weight Hyaluronic Acid Topical Gel in the Treatment of Facial Seborrheic Dermatitis Final Report*. *J Clin Aesthet Dermatol*. 2014;7(5):15-18.
- Schlesinger TE**, Cohen JL, Ellison S. *Purpura and Fillers: A Review of Pre-Procedural, Intra-Procedural, and Post-Procedural Considerations*. *J Drugs Dermatol* 2013;12(10):611-615.

- Schlesinger TE**, Powell CR. *Efficacy and Tolerability of Low Molecular Weight Hyaluronic Acid Sodium Salt 0.2% Cream in Rosacea*. J Drugs Dermatol 2013;12(6):664-667.
- Schlesinger TE**, Powell CR. *Efficacy and Safety of a Low-Molecular Weight Hyaluronic Acid Topical Gel in the Treatment of Facial Seborrheic Dermatitis*. J Clin Aesthet Dermatol 2012;5(10):27-30.
- Schlesinger TE**, Condry A. *Skin Rejuvenation with Blue Light Photodynamic Therapy Using an Ester of Aminolevulinic Acid: A Split Face Study of the Differential Effect of Microdermabrasion*. Presented as a poster at the 2011 American Society for Dermatologic Surgery Annual Meeting November 3-6, 2011.
- Schlesinger TE**, Condry A. *Case Study Using a Novel Absorbable Surgical Stapling Device in Private Practice Dermatologic Surgery*. Presented as a poster at the 2011 American Society for Dermatologic Surgery Annual Meeting November 3-6, 2011.
- Schlesinger TE**, Mills O, Repaire R. *An open community-based trial with combination topical (1% salicylic acid & 4% benzoyl peroxide/2% salicylic acid & 8% benzoyl peroxide) and 5% tocopherol therapy for acne vulgaris*. Presented as a poster at the 2010 American Academy of Dermatology Annual Meeting March 5-9, 2010.
- Schlesinger TE**, Mills O, Wrightington L. *Private practice evaluation of topical 10% L-ascorbic acid and 0.15% retinol*. Presented as a poster at the 2010 American Academy of Dermatology Annual Meeting March 5-9, 2010.
- Chang A, Tung RC, **Schlesinger TE**, Bergfeld WF, Dijkstra J, Kahn TA. *Familial Cutaneous Mastocytosis*. Pediatric Dermatology 2001;18(4):271-6.
- Lyons JA, **Schlesinger TE**, Smith MD, Camisa C, Turner JM, Crowe J, Crownover RL. *Successful breast conservation in a patient with epidermolysis bullosa simplex*. Breast Journal 1999;5(6):404-406.
- Schlesinger TE**, McCarron K, Camisa C, Anhalt GJ. *Paraneoplastic pemphigus occurring in a patient with B-cell Non-Hodgkin's lymphoma*. Cutis 1998;61(2):94-6.
- Schlesinger TE**, Gay JD, Bergfeld WF, Camisa C. *Oral erosive lichen planus occurring during interferon alpha therapy for hepatitis C virus infection*. J Am Acad Dermatol 1997; 36:1023-5.

Schlesinger TE, McCarron K, Anhalt GJ, Camisa C. *Paraneoplastic pemphigus*. Poster at the American Academy of Dermatology Annual Meeting, San Francisco, California, March 21-26, 1997.

Schlesinger TE, Tomecki, KJ. *Drug induced toxic epidermal necrolysis., the Cleveland Clinic experience.* (in preparation).

LECTURES

Schlesinger TE (2021, February). *The Dermatology Digest (BPDCN Podcast Series) Advanced Skin Cancer Therapies.*

Schlesinger TE (2021, January). *Surveying the Dermatological Treatment Landscape. HCPLive (Podcast): New therapies on the horizon and those that have already proven efficacious.*

Schlesinger TE (2020, December). *Using Hedgehog Inhibitors for Treating Advanced Basal Cell Carcinoma.* 23rd Annual Mount Sinai Winter Symposium: Advances in Medical and Surgical Dermatology. Virtual Presentation.

Schlesinger TE (2020, November). *Advanced Therapy (In Session: New Developments in the Diagnosis, Prevention, and Treatment of Skin Cancer).* 40th Anniversary Fall Clinical Dermatology Conference. Virtual Presentation.

Schlesinger TE (2020, November). *Hedgehog Inhibition: The Right Pathway for the Right Patient.* 40th Anniversary Fall Clinical Dermatology Conference. Virtual Presentation.

Schlesinger TE (2020, November). *Using Fillers Off the Face for a Natural Lift.* AMWC 18th Aesthetic & Anti-Aging Medicine World Congress. Virtual. Session Co-Chair.

Schlesinger TE (2020, November). *Digital Marketing – Taking Your Strategy to the Next Level.* 9th Annual Dermatology & Aesthetic Surgery International League Congress (DASIL). Virtual Presentation.

Schlesinger TE (2020, September). *Managing Acne Scars – Achieving Optimal Results.* Vegas Cosmetic Surgery & Aesthetic Dermatology. Las Vegas, Nevada. Virtual Presentation

Schlesinger TE (2020, August). *Overview of Cannabinoid Therapeutics.* 12th Annual 5-Continent Congress. Virtual Presentation.

Schlesinger TE (2020, July). *Demystifying PRP.* Music City Symposium for Cosmetic Advances & Laser Education (SCALE). Virtual Presentation.

- Schlesinger TE** (2020, July). *Global Facial Optimization: Using Fillers Off the Mid-Face for Natural Correction*. Music City Symposium for Cosmetic Advances & Laser Education (SCALE). Virtual Presentation.
- Schlesinger TE** (2019, October). *Microneedling and PRP – How I Do It*. Global Aesthetics Conference. Miami, Florida.
- Schlesinger TE** (2019, October). *How to Find and Keep Your Patients – Sell a Feeling!* Global Aesthetics Conference. Miami, Florida.
- Schlesinger TE** (2019, October). *Global Facial Optimization: Using Fillers Off the Mid-Face for a Natural Lift*. Global Aesthetics Conference. Miami, Florida.
- Schlesinger TE** (October, 2019). *A Multidisciplinary Expert-Driven Consensus on the Evolving Treatment of Patients with Advanced Cutaneous Squamous Cell Carcinoma*. American Society for Dermatologic Surgery 2019 Annual Meeting, Chicago, Illinois.
- Schlesinger TE** (2019, August). *Finessing the Jawline: What Anatomy Teaches us and Combination Treatment*. 11th Annual 5-Continent Congress, Barcelona, Spain.
- Schlesinger TE** (2019, August). *Medical Photography and Privacy – Tips and Tricks*. 11th Annual 5-Continent Congress, Barcelona, Spain.
- Schlesinger TE** (2019, June). *Building and Using a Call Center*. Vegas Cosmetic Surgery & Aesthetic Dermatology. Las Vegas, Nevada.
- Schlesinger TE** (2019, June). *Global Facial Optimization: Using Fillers Off the Mid-Face for a Natural Lift*. Vegas Cosmetic Surgery & Aesthetic Dermatology. Las Vegas, Nevada.
- Schlesinger TE** (2019, June). *Microneedling and PRP – How I Do It*. Vegas Cosmetic Surgery & Aesthetic Dermatology. Las Vegas, Nevada.
- Schlesinger TE** (2019, June). *Future-Proof Your Practice. How to Leverage Artificial Intelligence, Automation & The Cloud*. Industry Session at Vegas Cosmetic Surgery & Aesthetic Dermatology. Las Vegas, Nevada.
- Schlesinger TE** (2019, March). *Building a Research Center – How to Start and What to Build*. The American Academy of Dermatology 2019 Annual Meeting. Washington, DC.
- Schlesinger TE** (2019, March). *Medical Photography – Tips and Tricks*. The American Academy of Dermatology 2019 Annual Meeting. Washington, DC.

- Schlesinger TE** (2019, February) *Artificial Intelligence in Dermatology – An Overview*. IMCAS World Congress 2019. Paris, France.
- Schlesinger TE** (2019, February) *Tips for Hiring and Managing Staff*. IMCAS World Congress 2019. Paris, France.
- Schlesinger TE** (2019, February) *How to Find and Keep Your Patients? Sell a Feeling!* IMCAS World Congress 2019. Paris, France.
- Schlesinger TE** (2018, August) *Using Surveys and Questionnaires to Grow a Dermatology Practice*. 5 Continent Congress. Barcelona, Spain.
- Schlesinger TE** (2018, August) *Emerging Therapies in Cutaneous Oncology*. 5 Continent Congress. Barcelona, Spain.
- Schlesinger TE** (2018, August) *Microneedling and PRP – How I do it*. 5 Continent Congress. Barcelona, Spain.
- Schlesinger TE** (2018, August) *New and Emerging Therapies in Cutaneous Oncology*. The American Academy of Dermatology 2018 Summer Meeting. Chicago, Illinois.
- Schlesinger TE** (2018, June). *Building and Using a Call Center*. Vegas Cosmetic Surgery and Aesthetic Dermatology. Las Vegas, Nevada.
- Schlesinger TE** (2018, June). *Combining Microneedling and Platelet-Rich Plasma in Your Cosmetic Practice*. Vegas Cosmetic Surgery and Aesthetic Dermatology. Las Vegas, Nevada.
- Schlesinger TE** (2018, April). *Tips for Hiring and Managing Staff*. The American Society for Laser Medicine and Surgery 2018 Annual Meeting. Dallas, Texas.
- Schlesinger TE** (2018, February). S063 Pearls from the Masters of Dermatological Surgery – Microneedling and Platelet Rich Plasma (PRP). The American Academy of Dermatology 2018 Annual Meeting. San Diego, California.
- Schlesinger TE** (2018, February). U041 Medical Photography. The American Academy of Dermatology 2018 Annual Meeting. San Diego, California.
- Schlesinger TE** (2017, October). Understanding PRP – Hype or Real Results?. The Dermatologic and Aesthetic Surgery International League. Shanghai, China.
- Schlesinger TE** (2017, October). Microneedles – What is the Truth, What Really Works? (As part of a StrataMed Product Theater). The Dermatologic and Aesthetic Surgery International League. Shanghai, China.

- Schlesinger TE** (2017, October). Complications of Microneedling. The Dermatologic and Aesthetic Surgery International League. Shanghai, China.
- Schlesinger TE** (2017, October). Using Microimmunoarray Assays in Dermatological Research. The Dermatologic and Aesthetic Surgery International League. Shanghai, China.
- Schlesinger TE** (2017, October). Using Microneedling for Scarring and Pigment Concerns. The Dermatologic and Aesthetic Surgery International League. Shanghai, China.
- Schlesinger TE** (2017, October). Finessing Cosmetic Techniques – Midface Correction. The Dermatologic and Aesthetic Surgery International League. Shanghai, China.
- Schlesinger TE** (2017, October). The Future of Social Media in Medicine. The Dermatologic and Aesthetic Surgery International League. Shanghai, China.
- Schlesinger TE** (2017, September). Microneedles: What is the Truth, What Really Works? 8th 5-Continent Congress (5CC). Barcelona, Spain.
- Schlesinger TE** (2017, August). Building a Research Center – How to Start and What to Build. 8th 5-Continent Congress (5CC). Barcelona, Spain.
- Schlesinger TE** (2017, June). Global Facial Aesthetic Optimization Using a PMMA Dermal Filler – Anatomical to Clinical Translation. Vegas Cosmetic Surgery and Aesthetic Dermatology 2017. Las Vegas, NV.
- Schlesinger TE** (2017, June). Acne Scarring. What’s New and Upcoming in Treatment? Vegas Cosmetic Surgery and Aesthetic Dermatology 2017. Las Vegas, NV.
- Schlesinger TE** (2017, January). Faculty Member. Virgin Derm17. Microneedles – What is the Truth, What Really Works? St. Thomas, USVI.
- Schlesinger TE** (2017, January). Faculty Member. Virgin Derm17. Noninvasive Body Contouring and Fat Reduction – Faculty Experience Panel Member, St. Thomas, USVI.
- Schlesinger TE** (2017, January). Faculty Member. Virgin Derm17. Clinical Role Play – What Would You Do? (Panel Member) St. Thomas, USVI.
- Schlesinger TE** (2016, October). Faculty Member. Needling Workshop – New Innovations in Combination Therapy with Microneedling. The Dermatologic and Aesthetic Surgery International League. Dubai, UAE.

- Schlesinger TE** (2016, October). Global Facial Aesthetic Optimization Using a PMMA/Collagen Based Dermal Filler – Anatomical to Clinical Translation. The Dermatologic and Aesthetic Surgery International League. Dubai, UAE.
- Schlesinger TE** (2016, October). **Session Chair.** Improving Patient Satisfaction. The Dermatologic and Aesthetic Surgery International League. Dubai, UAE.
- Schlesinger TE** (2016, October). Getting Started in Clinical Research: Where do I begin? The Dermatologic and Aesthetic Surgery International League. Dubai, UAE.
- Schlesinger TE** (2016, October). Lasers and Lights for Acne. The Dermatologic and Aesthetic Surgery International League. Dubai, UAE.
- Schlesinger TE** (2016, October). Acne Scarring – What’s New and Upcoming in Treatment. The Dermatologic and Aesthetic Surgery International League. Dubai, UAE.
- Schlesinger TE** (2016, October). Combining Modalities for an Ideal Chin Augmentation. The Dermatologic and Aesthetic Surgery International League. Dubai, UAE.
- Schlesinger TE** (2016, October). **Plenary Session.** New Thoughts on Social Media. The Dermatologic and Aesthetic Surgery International League. Dubai, UAE.
- Schlesinger TE** (2016, June). Blunt Tipped Cannulas: Do They Really Minimize Complications? Vegas Cosmetic Surgery and Aesthetic Dermatology 2016. Las Vegas, NV.
- Schlesinger TE** (2016, June). Lasers and Lights for Acne - Where Are We Now? Vegas Cosmetic Surgery and Aesthetic Dermatology 2016. Las Vegas, NV.
- Schlesinger TE** (2016, June). CO₂ Laser Resurfacing: Why This Is Still An Important Procedure In My Practice. Vegas Cosmetic Surgery and Aesthetic Dermatology 2016. Las Vegas, NV.
- Schlesinger TE** (2016, June). Patient Satisfaction Surveys - How to Make Them Work for You. Vegas Cosmetic Surgery and Aesthetic Dermatology 2016. Las Vegas, NV.
- Schlesinger TE** (2016, June). "Modern Aesthetics" Lightening Round-Three Pearls in Three Minutes. Panel Member and Speaker. Vegas Cosmetic Surgery and Aesthetic Dermatology 2016. Las Vegas, NV.
- Schlesinger TE.** (2015, September). Should You Hire a PA? *New Derm LIVE*. Hollywood, CA.

- Schlesinger TE.** (2015, September). What Your Overhead Should Look Like Over Time. *New Derm LIVE*. Hollywood, CA.
- Schlesinger TE.** (2015, June). Patient Satisfaction Surveys – How to Make Them Work For You. *Vegas Cosmetic Surgery & Aesthetic Dermatology*. Las Vegas, NV.
- Schlesinger TE.** (2015, June). Lasers and Lights for Acne – Where are we Now?. *Vegas Cosmetic Surgery & Aesthetic Dermatology*. Las Vegas, NV.
- Schlesinger TE.** (2014, June). Leadership in the Medical Aesthetic Practice. *Vegas Cosmetic Surgery & Aesthetic Dermatology*. Las Vegas, NV.
- Schlesinger TE.** (2014, June). Maximizing Medical Reimbursement. *Vegas Cosmetic Surgery & Aesthetic Dermatology*. Las Vegas, NV.
- Schlesinger TE.** (2014, June). Surveys - What We Have Learned on Asking How We Are Doing. *Vegas Cosmetic Surgery & Aesthetic Dermatology*. Las Vegas, NV.
- Schlesinger TE.** (2014, May). Inflammatory Facial Dermatoses. *Florida Society of Dermatology Physician Assistants New Wave Dermatology Symposium*. St. Petersburg, FL.
- Schlesinger TE.** (2014, April). Mohs Surgery: Curing the Cancer. *Georgia Dermatology Physician Assistants PEARLS Conference*. Atlanta, GA.
- Schlesinger TE.** (2014, April). Inflammatory Dermatoses. *Georgia Dermatology Physician Assistants PEARLS Conference*. Atlanta, GA.
- Schlesinger TE.** (2013, September). Achieving the Promise of EHR. *South Carolina Medical Association Board Retreat*. Charlotte, NC.
- Schlesinger TE.** (2013, September). ICD-10 Conversion and Implementation. *South Carolina Medical Association Board Retreat*. Charlotte, NC.
- Schlesinger TE.** (2012, June). Maximizing Medical Reimbursement. *Georgia Society of Dermatology and Dermatologic Surgery*. Hilton Head, SC.
- Schlesinger TE.** (2012, June). A Social Media Guidebook for the Dermatology Practice. *Georgia Society of Dermatology and Dermatologic Surgery*. Hilton Head, SC.

Schlesinger TE. (2012, January). Implementing an EHR. *Orlando Dermatology Aesthetics and Clinical Conference*. Orlando, FL.

Schlesinger TE. (2012, January). Maximizing Medical Reimbursement. *Orlando Dermatology Aesthetics and Clinical Conference*. Orlando, FL.

Schlesinger TE. (2012, January). Social Media for the Dermatology Practice. *Orlando Dermatology Aesthetics and Clinical Conference*. Orlando, FL.

Schlesinger TE. (2011, October). Pearls in Dermatology for the Internist. *American College of Physicians South Carolina Chapter Meeting*. Charleston, SC.

Schlesinger TE. (2011, April). Volunteerism in Your Community: Free and Low Cost Health Screenings - Free Screenings for Skin Cancer. *2011 Global Humanitarian Summit*. Atlanta, GA.

Schlesinger TE. (2011, April). First Aid for Skin: Infection, Wound and Frostbite Management. *2011 South Carolina Medical Association Annual Meeting*. Greenville, SC.